Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Company Strengthens IP Portfolio and Prepares for EB-003 IND Submission

Mar. 30, 2026 at 7:54am

Got story updates? Submit your updates here. ›

Enveric Biosciences, a biotechnology company advancing next-generation neuroplastogenic small molecules, reported positive preclinical results for its lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression, despair, and post-traumatic stress disorder (PTSD). The company also announced the withdrawal of a patent challenge, continued strengthening of its IP portfolio, and progress towards submitting an IND application for EB-003.

Why it matters

Enveric's focus on developing non-hallucinogenic neuroplastogens for mental health disorders represents an innovative approach to addressing unmet needs in this space. The positive preclinical data for EB-003 and the company's efforts to protect its intellectual property suggest potential for this candidate to deliver therapeutic benefits without the constraints associated with psychedelic compounds.

The details

Enveric reported that EB-003 demonstrated statistically significant improvements in preclinical models of severe chronic depression and PTSD. The company also achieved key manufacturing milestones for EB-003 and identified additional neuroplastogen candidates with potential to promote BDNF signaling, a target for neurodegenerative diseases. Enveric successfully defended its IP portfolio, with the withdrawal of a patent challenge by Gilgamesh Pharmaceuticals related to a compound acquired by AbbVie. The company continued to strengthen its expansive IP, receiving multiple patents and notices of allowance for its EVM301 and EVM401 compound series.

  • In 2025, Enveric reported positive preclinical results for EB-003.
  • In Q4 2025, Enveric raised $4.9 million from a warrant inducement and at-the-market offering.
  • In January 2026, Enveric raised $1.5 million from a registered direct offering.
  • In February 2026, Enveric raised $1.45 million from an at-the-market offering.

The players

Enveric Biosciences

A biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics to address psychiatric and neurological disorders.

Joseph Tucker, Ph.D.

Director and CEO of Enveric Biosciences.

Gilgamesh Pharmaceuticals

A pharmaceutical company that filed a Post-Grant Review (PGR) petition against Enveric's patent, which was ultimately withdrawn.

AbbVie, Inc.

A pharmaceutical company that acquired the bretisilocin (GM-2505) molecule, which appears relevant to the patents Enveric was defending.

Got photos? Submit your photos here. ›

What they’re saying

“The year 2025 was a year of important scientific progress for Enveric as we further strengthened the mechanistic rationale for our lead candidate, EB-003, a non-hallucinogenic neuroplastogen, being developed for the treatment of underserved mental health conditions.”

— Joseph Tucker, Ph.D., Director and CEO of Enveric Biosciences

“Our excitement around EB-003 has been further amplified by recent, independent academic research that has helped to provide additional mechanistic clarity for the field. Researchers have shown intracellular pathways downstream of 5-HT 2A in the experimental models, with signal pathways potentially mediating antidepressant- and anxiolytic-like effects, distinct from pathways resulting in hallucinations.”

— Joseph Tucker, Ph.D., Director and CEO of Enveric Biosciences

What’s next

Enveric is working towards a streamlined IND application for EB-003 in preparation of the initiation of a first-in-human Phase 1 clinical trial.

The takeaway

Enveric's focus on developing non-hallucinogenic neuroplastogens represents an innovative approach to addressing unmet needs in mental health disorders. The positive preclinical data for EB-003 and the company's efforts to protect its intellectual property suggest potential for this candidate to deliver therapeutic benefits without the constraints associated with psychedelic compounds.